Lack of Association of Clinical Factors (SAMe-TT2R2) with @entity5060 / XXXX Genotype and Anticoagulation Control Quality.

@entity1 @entity286 @entity2643 @entity5058 @entity71120 @entity5060 @entity955 @entity1229
BACKGROUND AND PURPOSE: Advantages of new oral anticoagulations may be greater in @entity955 ( @entity955 ) @entity1 of poor anticoagulation control with @entity1229 . The SAMe-TT2R2 scoring system, based on clinical variables, was recently developed to aid in identifying these @entity1 . In this study, we investigated the association of this clinical composite score with genetic factors related @entity1229 dosing and the quality of anticoagulation control. METHODS: Clinical and genetic data were collected from 380 consecutive Korean @entity1 with @entity955 (CHA2DS2-VASc score, 3.5  1.8) who were followed for an average of 4 years. We evaluated factors associated with time in therapeutic range (TTR, INR 2-3), including the @entity5060 and @entity5058 genotypes and the SAMe-TT2R2 score (Sex female, Age <60 years, Medical history [>two co-morbidities], Treatment [interacting drugs, e.g., @entity2643 ], @entity286 use within 2 years [doubled], and Race non-white [doubled]). RESULTS: The average SAMe-TT2R2 score was 3.4  0.9, range 2-7; and 153 @entity1 (40.2%) had SAMe-TT2R2 scores >= 4. Time in specific INR ranges varied depending on the @entity5058 genotype but not with the @entity5060 genotype or the SAMe-TT2R2 score. TTR was higher in @entity1 with the @entity5058 @entity71120 than in @entity5058 TT (61.7  16% vs. 56.7  17.4%, P=0.031). Multivariate testing showed that @entity5058 genotype but not the SAMe-TT2R2 score was significantly associated with labile INRs. There was no correlation between the SAMe-TT2R2 scores and pharmacogenetic data. CONCLUSIONS: A genetic factor, but none of the common clinical and demographic factors, as combined in the SAMe-TT2R2 score, was associated with the quality of anticoagulation control in Korean @entity1 with @entity955 .
